Lynparza On Track For Broad Frontline Use In Prostate Cancer

Leading PARP Inhibitor’s Uses Keep Expanding

AstraZeneca and Merck & Co’s latest results put them far ahead of competitors in prostate cancer in reaching patient regardless of their mutational status.

AstraZeneca
Lynparza is one of a handful of targeted cancer therapies currently leading AstraZeneca's growth. • Source: Shutterstock: Elzbieta Krzysztof

AstraZeneca and Merck & Co have presented more detailed data confirming Lynparza’s benefits as a frontline combination therapy in prostate cancer regardless of mutation status, paving the way for a major expansion of its use.

The partners first unveiled topline data from the PROpel Phase III trial in September last year but have now released fuller data showing that Lynparza (olaparib) produced improvement in radiographic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By 

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By 

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

In partnership with

Podcast Series: Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials

Insights from Novotech on Evolving Trends Impacting Global Clinical Development